Paradigms and controversies in the treatment of HIV-related Burkitt lymphoma

Adam M. Petrich; Joseph A. Sparano; Samir Parekh

doi:10.1155/2012/403648

Paradigms and controversies in the treatment of HIV-related Burkitt lymphoma

Adam M. Petrich, Joseph A. Sparano, Samir Parekh

Medicine

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Burkitt lymphoma (BL) is a very aggressive subtype of non-Hodgkins lymphoma that occurs with higher frequency in patients with HIV/AIDS. Patients with HIV-related BL (HIV-BL) are usually treated with high-intensity, multi-agent chemotherapy regimens. The addition of the monoclonal antibody Rituximab to chemotherapy has also been studied in this setting. The potential risks and benefits of commonly used regimens are reviewed herein, along with a discussion of controversial issues in the practical management of HIV-BL, including concurrent anti-retroviral therapy, treatment of relapsed and/or refractory disease, and the role of stem cell transplantation.

Original language	English (US)
Article number	403648
Journal	Advances in Hematology
Volume	2012
DOIs	https://doi.org/10.1155/2012/403648
State	Published - 2012

ASJC Scopus subject areas

Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1155/2012/403648

Cite this

@article{e97b74466bea4557a2e8784060bb9403,

title = "Paradigms and controversies in the treatment of HIV-related Burkitt lymphoma",

abstract = "Burkitt lymphoma (BL) is a very aggressive subtype of non-Hodgkins lymphoma that occurs with higher frequency in patients with HIV/AIDS. Patients with HIV-related BL (HIV-BL) are usually treated with high-intensity, multi-agent chemotherapy regimens. The addition of the monoclonal antibody Rituximab to chemotherapy has also been studied in this setting. The potential risks and benefits of commonly used regimens are reviewed herein, along with a discussion of controversial issues in the practical management of HIV-BL, including concurrent anti-retroviral therapy, treatment of relapsed and/or refractory disease, and the role of stem cell transplantation.",

author = "Petrich, {Adam M.} and Sparano, {Joseph A.} and Samir Parekh",

year = "2012",

doi = "10.1155/2012/403648",

language = "English (US)",

volume = "2012",

journal = "Advances in Hematology",

issn = "1687-9104",

publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Paradigms and controversies in the treatment of HIV-related Burkitt lymphoma

AU - Petrich, Adam M.

AU - Sparano, Joseph A.

AU - Parekh, Samir

PY - 2012

Y1 - 2012

N2 - Burkitt lymphoma (BL) is a very aggressive subtype of non-Hodgkins lymphoma that occurs with higher frequency in patients with HIV/AIDS. Patients with HIV-related BL (HIV-BL) are usually treated with high-intensity, multi-agent chemotherapy regimens. The addition of the monoclonal antibody Rituximab to chemotherapy has also been studied in this setting. The potential risks and benefits of commonly used regimens are reviewed herein, along with a discussion of controversial issues in the practical management of HIV-BL, including concurrent anti-retroviral therapy, treatment of relapsed and/or refractory disease, and the role of stem cell transplantation.

AB - Burkitt lymphoma (BL) is a very aggressive subtype of non-Hodgkins lymphoma that occurs with higher frequency in patients with HIV/AIDS. Patients with HIV-related BL (HIV-BL) are usually treated with high-intensity, multi-agent chemotherapy regimens. The addition of the monoclonal antibody Rituximab to chemotherapy has also been studied in this setting. The potential risks and benefits of commonly used regimens are reviewed herein, along with a discussion of controversial issues in the practical management of HIV-BL, including concurrent anti-retroviral therapy, treatment of relapsed and/or refractory disease, and the role of stem cell transplantation.

UR - http://www.scopus.com/inward/record.url?scp=84861024042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861024042&partnerID=8YFLogxK

U2 - 10.1155/2012/403648

DO - 10.1155/2012/403648

M3 - Review article

C2 - 22570659

AN - SCOPUS:84861024042

SN - 1687-9104

VL - 2012

JO - Advances in Hematology

JF - Advances in Hematology

M1 - 403648

ER -

Paradigms and controversies in the treatment of HIV-related Burkitt lymphoma

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this